Abstract:BackgroundNeoadjuvant chemotherapy is recommended for BRPC and LAPC planned resection. PD-1 antibody alone failed in advanced pancreatic cancer previously, but chemotherapy combined with PD-1 antibody are promising. The aim of this study is to investigate whether neoadjuvant chemotherapy plus PD-1 antibody can result in better outcomes.MethodsThis is a randomized, controlled, open-label phase II study including patients with BRPC or LAPC. Modified FOLFIRINOX (mFFX) is used as neoadjuvant chemotherapy. Patients will be randomly allocated into two groups: mFFX group and mFFX plus PD-1 antibody group (PD-1 group). Imaging evaluation will be discussed by the MDT. Surgical resection will be performed if the MDT confirms the resectability. (NCT03983057).ResultsFrom March 4th 2019 to August 1st 2021, 146 patients were enrolled and randomized. Of the 146 patients, 62 (42.4%) were BRPC and 84 (57.5%) were LAPC. Among them, 115 patients received at least four cycles of mFFX or mFFX plus PD-1 antibody and completed radiological evaluation at least once. Grade 3 neutropenia was common in both groups. And in mFFX plus PD-1 antibody group, immune-related adverse events (irAEs) happened in seven patients (9.7%), including rash (3 patients, all were Grade 1), hepatic AE (2 patients Grade 3, 1 patient Grade 2), renal AE (2 patients, both Grade 2), and hyperglycemia with diabetic ketoacidosis (2 patients). All of the seven patients were relieved after proper treatment. Radiological partial response was noted in 13.3% patients in mFFX group, and 26.9% in mFFX plus PD-1 antibody group. Notably, for BRPC patients, the radiological partial response was 13.0% and 36.3% in two groups, respectively. The resection rate was similar in the two groups (47.4% and 51.7%). R0 resections were performed in 70.3% and 86.6% patients, respectively. However, for LAPC patients, mFFX plus PD-1 antibody group was noted in a higher resection rate (37.1% vs. 48.0%). The survival data are not mature at present.ConclusionsModified FOLFIRINOX plus PD-1 antibody is feasible and well-tolerated for BRPC and LAPC patients. The study will be continued and the detailed data will be reported.Clinical trial identificationNCT03983057.Legal entity responsible for the studyThe authors.FundingKey clinical study foundation of the First Affiliated Hospital, Zhejiang University School of Medicine.DisclosureAll authors have declared no conflicts of interest. BackgroundNeoadjuvant chemotherapy is recommended for BRPC and LAPC planned resection. PD-1 antibody alone failed in advanced pancreatic cancer previously, but chemotherapy combined with PD-1 antibody are promising. The aim of this study is to investigate whether neoadjuvant chemotherapy plus PD-1 antibody can result in better outcomes. Neoadjuvant chemotherapy is recommended for BRPC and LAPC planned resection. PD-1 antibody alone failed in advanced pancreatic cancer previously, but chemotherapy combined with PD-1 antibody are promising. The aim of this study is to investigate whether neoadjuvant chemotherapy plus PD-1 antibody can result in better outcomes. MethodsThis is a randomized, controlled, open-label phase II study including patients with BRPC or LAPC. Modified FOLFIRINOX (mFFX) is used as neoadjuvant chemotherapy. Patients will be randomly allocated into two groups: mFFX group and mFFX plus PD-1 antibody group (PD-1 group). Imaging evaluation will be discussed by the MDT. Surgical resection will be performed if the MDT confirms the resectability. (NCT03983057). This is a randomized, controlled, open-label phase II study including patients with BRPC or LAPC. Modified FOLFIRINOX (mFFX) is used as neoadjuvant chemotherapy. Patients will be randomly allocated into two groups: mFFX group and mFFX plus PD-1 antibody group (PD-1 group). Imaging evaluation will be discussed by the MDT. Surgical resection will be performed if the MDT confirms the resectability. (NCT03983057). ResultsFrom March 4th 2019 to August 1st 2021, 146 patients were enrolled and randomized. Of the 146 patients, 62 (42.4%) were BRPC and 84 (57.5%) were LAPC. Among them, 115 patients received at least four cycles of mFFX or mFFX plus PD-1 antibody and completed radiological evaluation at least once. Grade 3 neutropenia was common in both groups. And in mFFX plus PD-1 antibody group, immune-related adverse events (irAEs) happened in seven patients (9.7%), including rash (3 patients, all were Grade 1), hepatic AE (2 patients Grade 3, 1 patient Grade 2), renal AE (2 patients, both Grade 2), and hyperglycemia with diabetic ketoacidosis (2 patients). All of the seven patients were relieved after proper treatment. Radiological partial response was noted in 13.3% patients in mFFX group, and 26.9% in mFFX plus PD-1 antibody group. Notably, for BRPC patients, the radiological partial response was 13.0% and 36.3% in two groups, respectively. The resection rate was similar in the two groups (47.4% and 51.7%). R0 resections were performed in 70.3% and 86.6% patients, respectively. However, for LAPC patients, mFFX plus PD-1 antibody group was noted in a higher resection rate (37.1% vs. 48.0%). The survival data are not mature at present. From March 4th 2019 to August 1st 2021, 146 patients were enrolled and randomized. Of the 146 patients, 62 (42.4%) were BRPC and 84 (57.5%) were LAPC. Among them, 115 patients received at least four cycles of mFFX or mFFX plus PD-1 antibody and completed radiological evaluation at least once. Grade 3 neutropenia was common in both groups. And in mFFX plus PD-1 antibody group, immune-related adverse events (irAEs) happened in seven patients (9.7%), including rash (3 patients, all were Grade 1), hepatic AE (2 patients Grade 3, 1 patient Grade 2), renal AE (2 patients, both Grade 2), and hyperglycemia with diabetic ketoacidosis (2 patients). All of the seven patients were relieved after proper treatment. Radiological partial response was noted in 13.3% patients in mFFX group, and 26.9% in mFFX plus PD-1 antibody group. Notably, for BRPC patients, the radiological partial response was 13.0% and 36.3% in two groups, respectively. The resection rate was similar in the two groups (47.4% and 51.7%). R0 resections were performed in 70.3% and 86.6% patients, respectively. However, for LAPC patients, mFFX plus PD-1 antibody group was noted in a higher resection rate (37.1% vs. 48.0%). The survival data are not mature at present. ConclusionsModified FOLFIRINOX plus PD-1 antibody is feasible and well-tolerated for BRPC and LAPC patients. The study will be continued and the detailed data will be reported. Modified FOLFIRINOX plus PD-1 antibody is feasible and well-tolerated for BRPC and LAPC patients. The study will be continued and the detailed data will be reported.

Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

FOLFOX Versus EOX As a Neoadjuvant Chemotherapy Regimen for Patients with Advanced Gastric Cancer

Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, for Resectable Advanced Pancreatic Adenocarcinoma: Continue or Stop?

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma

Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection

Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer

Postoperative complications following neoadjuvant therapy and surgery in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501).

Abstract A002: A phase II study of peri-operative modified FOLFIRINOX in localized pancreatic ductal adenocarcinoma (PDAC)

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas

Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma

Neoadjuvant Chemotherapy with Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: the Randomized, Phase III OPTICAL Trial

Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)

Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study

Adjuvant Therapy with Gemcitabine and Stereotactic Body Radiation Therapy Versus Gemcitabine Alone for Resected Stage II Pancreatic Cancer: A Prospective, Randomized, Open Label, Single-Center Trial.

Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort

PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.

Neoadjuvant Therapy for Resectable Pancreatic Cancer: a Narrative Review

146P Randomized Phase II Trial of Neoadjuvant Chemotherapy with Modified FOLFIRINOX Versus Modified FOLFIRINOX and PD-1 Antibody for Borderline Resectable and Locally Advanced Pancreatic Cancer (the CISPD-4 Study)